Chief Executive and Managing Director, OncoSil Medical
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive and Managing Director | OncoSil Medical | Biotech Dispatch (9 Sep 2026), Biotech Dispatch (18 Aug 2026), @AuManufacturing (28 May 2025), @AuManufacturing (22 Mar 2024) |
Stories naming Nigel Lange. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
OncoSil Medical says a Madrid hospital has treated its 100th Spanish pancreatic cancer patient with its brachytherapy device, as the ASX-listed company focuses on deepening use across its 11 treatment sites.
Australian device maker OncoSil Medical has won US FDA humanitarian exemption approval for its targeted radiation treatment for unresectable distal bile duct cancer, opening a path to American commercialisation in financial year 2027.
Manufacturing roundup: OncoSil Medical locks in commitments for an $8.7 million raise, Soilco completes its purchase of Martins Fertilizers, Avecho collects an R&D rebate, alongside items on apprenticeships, Myriota, Recce and Swinburne research.
Also thecfigroup.com·divestmergeacquire.com·redchip.com.au·wastemanagementreview.com.au
Roundup of Australian manufacturing news: OncoSil Medical's capital raising, an NT grant for a water monitoring project, GoZero's preferred supplier appointment, Micro-X's first Argus order, Aurora Labs' defence work, and Monash waste-recycling research.